Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy

Multiple patients have survived substantially beyond expected median survival, including onepatient who survived 28 months and several patients who remain alive with continued follow-up Lira-cel clinical trial featured in presentation at the International Society for Cell & Gene Therapy2026 Annual Meeting SAN JOSE, Calif., May 11, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or lira-cel, the Company's follicle-stimulating hormone receptor ("FSHR")-targeted CAR-T therapy being developed for the treatment of recurrent ovarian cancer.